1. Generics Bulletin
  2. >>Business
  3. >>Deals

PharOS takes Teva’s Arrow unit in Malta

Greece’s PharOS has struck a deal with Teva’s Arrow Pharm and Malta Enterprise to acquire certain assets of Arrow Pharm in Malta for an undisclosed sum. “This agreement will enable PharOS to take over the factory building, equipment and human resources of Arrow Pharm,” stated Malta’s ministry for the economy, investment and small businesses. “The takeover transition will occur over the next few months, with PharOS expected to be operational in Ħal Far, Malta, by mid-2018.”

Greece’s PharOS has struck a deal with Teva’s Arrow Pharm and Malta Enterprise to acquire certain assets of Arrow Pharm in Malta for an undisclosed sum. “This agreement will enable PharOS to take over the factory building, equipment and human resources of Arrow Pharm,” stated Malta’s ministry for the economy, investment and small businesses. “The takeover transition will occur over the next few months, with PharOS expected to be operational in Ħal Far, Malta, by mid-2018.”

Noting that it would initially be manufacturing finished dosageformsin Ħal Far, the privately-owned Greek firm said it would “eventually extend...

More from Deals

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By Dave Wallace

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By Dave Wallace

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline.

Polpharma Biologics And Fresenius Kabi Team Up On Entyvio Biosimilar

 
• By Urtė Fultinavičiūtė

Fresenius Kabi has picked up commercialization rights to Polpharma Biologics’ vedolizumab biosimilars in almost all markets. Still, the originator Takeda stands solid with no competition expected until at least 2032.

More from Business